17 April 2024
ReNeuron Group plc
("ReNeuron", the "Group" or the "Company")
Resignation of Chief Financial Officer
ReNeuron Group plc (in administration) (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces that John Hawkins will be stepping down as Chief Financial Officer ("CFO") of the Company with effect from 7 May 2024, in order to pursue other opportunities. Notwithstanding his departure, John will continue to provide support to the Company during the ongoing administration process.
Iain Ross, Executive Chairman, said:
"The Board takes this opportunity to thank John for his valued contribution to the Group during his tenure and wish him every success for the future."
Enquiries:
|
Cork Gully LLP |
+44 (0)20 7268 2150 or |
||
|
Stephen Cork, Joint Administrator |
reneuron@corkgully.com |
||
|
Mark Smith, Joint Administrator |
|
||
|
|
|
||
|
ReNeuron |
|||
|
Iain Ross, Executive Chairman |
Via Walbrook PR |
||
|
|
|
||
|
|
|
||
|
Allenby Capital Limited (Nominated Adviser and Broker) |
+44 (0)20 3328 5656 |
||
|
James Reeve/George Payne/ Dan Dearden-Williams (Corporate Finance) |
|
||
|
Stefano Aquilino/Kelly Gardiner (Sales & Corporate Broking) |
|
||
|
|
|
||
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
||
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
